Health Research Group Publications


Founded in 1971 by Sidney Wolfe, M.D. and Ralph Nader, Public Citizen’s Health Research Group promotes research-based, system-wide changes in health-care policy and drug safety. The work that we have done since 1995 is listed on this page in chronological order.

In testimony before a joint meeting of the Food and Drug Administration’s (FDA’s) Drug Safety and Risk Management and Anesthetic and Analgesic Drug Products Advisory Committees, Public Citizen urges the FDA to reject Intellipharmaceutics’ new version of oxycodone because, contrary to agency guidelines, the company has not conducted any human abuse potential studies of the drug to support a labeling claim that the drug deters intravenous abuse.

[Created on 7/26/2017]

In a letter to the Food and Drug Administration (FDA), Public Citizen urged the FDA not to approve liraglutide (Victoza) for the additional indication of reducing cardiovascular risk in type 2 diabetes patients because the clinical trial to support such approval failed to show any benefit in the 2,500 U.S. subjects in the trial. The study only showed a significant benefit in non-U.S. subjects.

[Created on 7/18/2017]

Ninety-one percent of the accountable care organizations (ACOs) that provide care to 9 million Medicare enrollees refuse to disclose their physician payment incentives, according to new research published today in the American Journal of Public Health. The study was conducted by researchers from Montefiore Medical Center in New York, City University of New York at Hunter College, and Public Citizen.

[Created on 7/12/2017]

Public Citizen sent a letter to members of Health Subcommittee of the U.S. House of Representatives’ Energy and Commerce Committee urging them to oppose draft legislation that would significantly expand marketing for unapproved uses of drugs and medical devices that have been approved or cleared by the FDA for at least one use. The legislation would undermine regulatory standards for ensuring that drugs and medical devices are safe and effective for each marketed use.

[Created on 7/11/2017]

Public Citizen opposes the Occupational Safety and Health Administration’s (OSHA’s) proposal to delay the deadline, from July 1 to December 1, 2017, for certain employers to submit injury and illness data electronically under its final rule entitled “Improve Tracking of Workplace Injuries and Illnesses”. The proposed postponement is unnecessary and will impede identification of workplace health and safety hazards.

[Created on 7/7/2017]

In an op-ed in RealClearHealth, Public Citizen harshly criticized a Trump administration proposal to eliminate the “ancillary provisions” of the Occupational Safety and Health Administration’s beryllium rule that would have extended specific new protections to construction and shipyard workers, including exposure assessments, personal protective equipment, medical surveillance and protected work areas.

[Created on 6/30/2017]

Proposal Would Continue to Put Workers in Construction and Shipyard Industries at Risk of Cancer and Chronic Beryllium Disease

[Created on 6/23/2017]

Public Citizen testified against the additional approval of liraglutide (Victoza) for reducing cardiovascular risk in diabetes patients because the clinical trial to support such approval failed to show any benefit in the 2,500 American subjects in the trial. The study only showed a significant benefit in non-U.S. subjects.

[Created on 6/20/2017]

Public Citizen requests that the Office for Human Research Protections (OHRP) immediately expand its ongoing compliance oversight investigation of the Surfactant Positive Airway Pressure and Pulse Oximetry Trial in Extremely Low Birth Weight Infants (SUPPORT) trial to evaluate newly uncovered information — recently obtained by Public Citizen under the Freedom of Information Act — that reveals additional major ethical lapses and failures to materially comply with key requirements of federal regulations for the protection of human subjects.

[Created on 6/14/2017]

Public Citizen today applauded the U.S. Food and Drug Administration (FDA) for urging Endo to take Opana ER off the market, while criticizing the fact that the FDA approved it and blasting Endo Pharmaceuticals’ defiant response to the request.

[Created on 6/9/2017]